Generation Bio Co. (GBIO)
NASDAQ: GBIO · Real-Time Price · USD
0.3904
+0.0304 (8.44%)
At close: May 12, 2025, 4:00 PM
0.3900
-0.0004 (-0.10%)
After-hours: May 12, 2025, 7:59 PM EDT
Generation Bio Co. Revenue
Generation Bio Co. had revenue of $8.72M in the quarter ending March 31, 2025, with 114.91% growth. This brings the company's revenue in the last twelve months to $24.56M, up 146.47% year-over-year. In the year 2024, Generation Bio Co. had annual revenue of $19.89M with 236.92% growth.
Revenue (ttm)
$24.56M
Revenue Growth
+146.47%
P/S Ratio
1.06
Revenue / Employee
$213,530
Employees
115
Market Cap
26.17M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GBIO News
- 5 days ago - Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference - GlobeNewsWire
- 2 months ago - Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 3 months ago - Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc. - Business Wire
- 4 months ago - Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases - GlobeNewsWire
- 7 months ago - Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress - GlobeNewsWire
- 8 months ago - Generation Bio to Present at the 2024 Cantor Global Healthcare Conference - GlobeNewsWire